Habibi-Amman schreef op 2 april 2019 10:32:
[...]
Throughout the year, building on our infrastructure
for ® was our focus. The new sales level has
driven further expansion of our raw materials production
capacity, and we have now initiated a second expansion
of that raw materials capacity along the same lines. The
new indications,
although they are still several years from
approval, would require much larger volumes of rhC1INH
than is possible using our current set-up,
and so we have
re-commenced development of a cattle version of rhC1INH.The cattle version of rhC1INH is even closer to natural
human C1 esterase inhibitor than the current version, and so
we do not anticipate any signifi cant obstacles to that cattle
version being approved in the future.